Musculoskeletal Oncology Therapeutics Market

Musculoskeletal Oncology Therapeutics Market: Global Industry Analysis and Opportunity Assessment 2016-2026

  • Ongoing
  • April 2020
  • REP-GB-1572
Musculoskeletal Oncology Therapeutics Market

  • US$5,000
  • US$7,500
  • US$10,000

This Musculoskeletal Oncology Therapeutics market study offers a comprehensive analysis of the business models, key strategies, and respective market shares of some of the most prominent players in this landscape. Along with an in-depth commentary on the key influencing factors, market statistics in terms of revenues, segment-wise data, region-wise data, and country-wise data are offered in the full study. This study is one of the most comprehensive documentation that captures all the facets of the evolving Musculoskeletal Oncology Therapeutics market.

Musculoskeletal oncology, also referred to as orthopedic oncology, is a highly specialised branch of orthopedic surgery. Musculoskeletal oncology is used in the treatment of  sculoskeletal cancers and tumours.

Bone and soft tissue tumors are quite rare and sometimes require reconstructive surgery.  Soft tissue sarcomas are more common than bone sarcomas. For 2016, the American Cancer Society estimates about 3,300 new cases for cancer of the bones and joints, and 12,310 new cases for soft tissue sarcomas.

Market Growth Analysis

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

Need granular data and specific insights that are hard to get?
There are three main types of bone cancers – 

Chondrosarcoma is more prevalent than other form of cancers and swift diagnosis and effective treatment remains a challenge for healthcare providers. Treatment with chemotherapy and radiotherapy do not remain the preferred choice of treatment in treating such type of tumor as clinical studies demonstrate no substantial improvements in the survival rate of the patients. Therefore, adequate surgical resection is the mainstay of treatment in case of chondrosarcoma. As estimated by the American Cancer Society, chondrosarcomas is more prevalent with 40% of cases developing in adults whereas less than 5% of cases occur in patients who are less than 20 years old.

Radiofrequency ablation has become the standard and most preferred choice of treatment in case of osteoid osteoma, a benign bone tumor that arises from osteoblasts. However, studies demonstrates its expanded application in palliative treatment of patients with painful bone metastasis. The ability to perform less invasive procedures often allows more efficient, less painful, and more cost-effective patient care. In addition, minimally invasive techniques, such as kyphoplasty, vertebroplasty, and acetabuloplasty may provide an alternative to major reconstructive surgery for patients with metastatic disease.

Global Musculoskeletal Oncology Therapeutics Market: Drivers & Restraints

One of the prime factors driving the global musculoskeletal oncology therapeutics market includes rapidly ageing population with increasing risk of developing cancer. Patients who had prior high-dose external radiation therapy or treatment with anti-cancer drugs are at higher risk of developing osteosarcoma. However, a small number of bone cancers also develop due to heredity defects of bones; people with metal implants, which doctors sometimes use to repair fractures, are more likely to develop osteosarcoma. In case of soft tissue sarcoma, adults with heredity disorders such as retinoblastoma, tuberous sclerosis, and Werner syndrome are at a higher risk of developing this type of cancer.

Development of safe and effective treatment procedures has also bolstered the growth of the musculoskeletal oncology therapeutics market. For example, image-guided surgery systems, primarily used in joints reconstruction, have been applied to orthopedic oncology. This may prove beneficial for areas such as the pelvis, where the complex anatomy makes the functional result difficult to interpret. Also, increasing focus of orthopedic oncologists to integrate advances in the surgical techniques by collaboration with subspecialties is also expected to boost the growth of the market during the forecast period, 2016-2026.

Unwanted complications associated with the radiation therapy, such as increased risk of wound complications and of post radiation fractures is hampering the musculoskeletal oncology therapeutics market growth. Additionally, high cost associated with the treatment and lack of awareness regarding the effective treatment therapies can also pose challenges to adoption during the forecast period.

Global Musculoskeletal Oncology Therapeutics Market: Segmentation       

Global Musculoskeletal Oncology Therapeutics Market: Overview

In the past few years, significant advancements have been made in treatment of musculoskeletal oncology related disorders. Yet, there is an urgent need to develop more sophisticated and highly advanced techniques to best manage hard-to-treat osteosarcomas.

Global Musculoskeletal Oncology Therapeutics Market: Region-wise Outlook

Global Musculoskeletal Oncology Therapeutics Market: Key Players

Key market players in the musculoskeletal oncology therapeutics market are Stryker Corporation, Accentus Inc., Roche Diagnostics, Amgen Inc., Novartis AG, Biogen dec, GlaxoSmithKline, Sanofi S.A., and Pfizer Inc.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

Unique Requirements? Customize this Report

  • Customize by Region, Country, Application, Product, & other segments
  • Integrate our Insights with your Existing Data
  • Determine the scope of the study to suit your requirements

Let FMI Help You!

  • Gain Insights on Key Musculoskeletal Oncology Therapeutics Market Impacting Forces
  • Know the Winning Strategies of Market Leaders
  • Get Deep-Dive Analysis on Each Segment
  • Identify the Sources that will Drive Top-Line Revenue

Musculoskeletal oncology therapeutics marketis segmented on the basis of diagnosis, treatment, end-user, and geography.

  • By Diagnosis
    • X- Ray
    • Magnetic resonance imaging (MRI) scan
    • Computed tomography (CT) scan
    • Positron emission tomography (PET) scan
    • Biopsy
  • By Treatment
    • Surgery
      • Amputation
      • Limb Salvage Surgery
      • Reconstructive Surgery
    • Chemotherapy
    • Radiation Therapy
    • Immunotherapy
    • Targeted Therapy
  • By End User
    • Multispecialty Hospitals
    • Cancer Research Institutes
    • Diagnostic Centers

Rising prevalence of musculoskeletal disorders is expected to increase emphasis on developing effective treatment procedures for cancers related to bones and soft tissues. Owing to these factors, the musculoskeletal oncology therapeutics market is expected to expand at a healthy growth rate during the forecast period.

Global Musculoskeletal Oncology Therapeutics Market: Region-wise Outlook

On the basis of region presence, musculoskeletal oncology therapeuticsmarket is segmented into seven key regions: North America, Latin America, and Eastern Europe, Western Europe, and Asia pacific excluding Japan (APEJ), Japan, Middle East and Africa. Europe and North America are the largest markets for musculoskeletal oncology therapeutics, owing to increased R&D investments and high level of awareness among end-users. Asia pacific represents immense growth opportunity for musculoskeletal oncology therapeutics market, owing to high population and increase in the prevalence of cancer.

Global Musculoskeletal Oncology Therapeutics Market: Key Players

The report covers exhaustive analysis on:

  • Market Segments
  • Market Dynamics
  • Market Size
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Value Chain

Regional analysis includes

  • North America (U.S., Canada)
  • Latin America (Mexico. Brazil)
  • Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)
  • Eastern Europe (Poland, Russia)
  • Asia Pacific (China, India, ASEAN, Australia & New Zealand)
  • Japan
  • Middle East and Africa (GCC, S. Africa, N. Africa)

Report Highlights:

  • Detailed overview of parent market
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current and projected market size in terms of volume and value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance
  • Must-have information for market players to sustain and enhance their market footprint.
Frequently Asked Questions

Why choose FMI?
  • With a global presence and a trusted partner to several Fortune 500 firms, FMI covers 1 billion+ data points to build a diversified portfolio for market benchmarking
  • Market Reports researched and peer reviewed by industry experts from across the globe
  • We follow a multi-dimensional method of analysis monitoring a three-layer data validation process
  • In addition to demand-side market assessment, our data triangulation methodology involves supply-side research
  • Primary research includes mandatory field interviews with stakeholders involved
  • Customizing reports according to client specification is also our forte
  • The current and future market size, covering each aspect and nuanced trends across key national and geographic markets
  • An overview of the market report, providing an imperative visual of the varied market subdivisions and overall forecast statistics in terms of value and volume
  • Extensive database and key dynamics elevating the market with varied verticals associated
  • Underlying Musculoskeletal Oncology Therapeutics Market forces that are compelling consumers or businesses to purchase the product
  • How novel technologies and consumer-centric innovations will create new value-adding opportunities for companies active in the Musculoskeletal Oncology Therapeutics Market
  • What will be environment and regulatory impacts on the market over the next decade
  • Investment Feasibility Matrix - It shows returns on investment, level of competition, success rate of investment, and potential risks associated with the market. The analysis shows that the competition is high in the established market, while the returns for short-term investment are also taken into consideration
  • Relative Maturity Mapping – The relative maturity is measured according to three growth phases (growth, maturity, decline)
  • Relative PLC (Product Life Cycle) – Analysis of the emergence of prominent players and competitive test prices which are driving factors behind every market. (expected market behavior, observed market behavior, expected market performance, observed market performance)
Get in touch
Harish Tiwari

Harish Tiwari

Global Head - Business Development

Pranay Mhaisekar

Pranay Mhaisekar

Business Development

* indicates mandatory fields
Our Clients

Request Sample Request customization Request Methodology